| Literature DB >> 24959854 |
Yangbo Liu1, Jingye Pan2, Keke Jin3, Cailong Liu1, Jing Wang1, Li Chen4, Lei Chen1, Jiandong Yuan1.
Abstract
Primary inoculation tuberculosis is a skin condition that develops at the site of inoculation of Mycobacterium tuberculosis in tuberculosis-free individuals. This report describes the diagnosis, treatment and >1 year follow-up of 30 patients presenting with acupuncture-induced primary inoculation tuberculosis. Our data provide a deeper insight into this rare route of infection of tuberculosis. We also review effective treatment options.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24959854 PMCID: PMC4069069 DOI: 10.1371/journal.pone.0100377
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Infiltration of a large number of chronic inflammatory cells among muscle fibers.
Many giant cells and epithelioid cells aggregated and formed multiple tubercles. Microabscess was present in the lesion region, and granulomatous inflammatory alteration was detected.
Figure 2A fresh lesion on the right side of the neck.
The ulcer was oval, with the largest diameter of about 5
Figure 3MRI scan of the hip on T1W1 reveals elevated signal intensity on the right gluteus maximus muscle.
Massive irregular, homogeneous, mass-like abnormal signal intensity with unclear boundary was observed in the gluteus maximus muscle, measuring about 151 cm×90 cm, and subcutaneous edema-like signal intensities were observed in the right hip.
Figure 4Hyperplasia of the knee joint synovium, grey and dark in color, with a soft texture, complicated by necrotic tissues.
Some knee joint synovium underwent caseous changes, and articular cartilage necrosis and desquamation were observed. Subchondral bone was exposed, and vermiform bone destruction was observed on the condyle of femur and the margin of the tibial plateau.
Figure 5Left and right upper lungs displayed diffuse, ground-glass shadows with increased intensity.
Figure 6Enhanced MRI scan shows tuberculous, ring-shaped, signal-intensified lesions in bilateral frontal and parietal lobes, centrum semiovale, peri-lateral ventricular region, basal ganglia regions, thalamus, brainstem and cerebellum.
Information on clinical features and treatments in 30 patients.
| Patient No. | Age/Gender | Diagnostic method | Incubation period (weeks) | Sinus | High fever | Operation | Anti-tuberculosis drug treatment protocols (months) | Efficacy of anti-TB drugs(group) | Follow-up time |
| Confirmed patients | |||||||||
| 01 | 67,M | PPD+, PCR+ | 3 | + | + | + | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 36 |
| 02 | 54,F | PPD+, PCR+ | 2 | + | + | + | 6(RFP/INH/PZA/EMB) & 12(RFP/INH) | III | 28 |
| 03 | 53,M | PPD+, PCR+ | 2 | + | + | + | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 40 |
| 04 | 50,M | PPD+, smear+, C+ | 1.5 | + | + | + | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 33 |
| 05 | 50,M | PPD+, smear+, C+ | 2 | + | + | + | 6(RFP/INH/PZA/EMB) & 12(RFP/INH) | III | 38 |
| 06 | 67,F | PPD+, smear+, C+ | 3 | + | + | + | 6(RFP/INH/PZA/EMB) & 12(RFP/INH) | III | 38 |
| 07 | 31,F | PPD+, PCR+ | 4 | + | - | - | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 30 |
| Suspected patients | |||||||||
| 01 | 71,F | PPD+ | 2 | + | + | + | 6(RFP/INH/PZA/EMB) & 12(RFP/INH) | III | 32 |
| 02 | 45,F | PPD+ | 3 | + | - | + | 2(RFP/INH/PZA/EMB) & 7(RFP/INH) | I | 36 |
| 03 | 40,M | PPD+ | 4 | + | - | + | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 30 |
| 04 | 60,F | PPD+, PCR- | 3 | - | - | - | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 38 |
| 05 | 64,M | PPD+ | 6 | - | - | - | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 36 |
| 06 | 60,F | PPD+ | 4.5 | + | + | - | 2(RFP/INH/PZA/EMB) & 7(RFP/INH) | I | 40 |
| 07 | 51,M | PPD+ | 3 | + | + | - | 2(RFP/INH/PZA/EMB) & 7(RFP/INH) | I | 28 |
| 08 | 56,M | PPD+ | 5 | + | - | - | 2(RFP/INH/PZA/EMB) & 7(RFP/INH) | I | 35 |
| 09 | 54,F | PPD+ | 3 | + | - | + | 2(RFP/INH/PZA/EMB) & 7(RFP/INH) | I | 33 |
| 10 | 48,F | PPD+ | 4 | + | - | + | 2(RFP/INH/PZA/EMB) & 7(RFP/INH) | I | 41 |
| 11 | 59,F | PPD+ | 4 | - | - | + | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 29 |
| 12 | 50,M | PPD+, smear+, C- | 2 | + | + | - | 2(RFP/INH/Avelox/EMB) & 7(RFP/INH) | I | 39 |
| 13 | 45,F | PPD+, smear+, C- | 1.5 | + | - | - | 6(RFP/INH/PZA/EMB) & 12(RFP/INH) | III | 36 |
| 14 | 48,F | PPD+ | 4 | + | + | + | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 35 |
| 15 | 48,M | PPD+ | 3 | - | + | + | 2(RFP/INH/PZA/EMB) & 7(RFP/INH) | I | 36 |
| 16 | 54,F | PPD+ | 2 | + | + | + | 6(RFP/INH/PZA/EMB) & 12(RFP/INH) | III | 35 |
| 17 | 44,F | PPD+ | 1 | - | + | + | 2(RFP/INH/PZA/EMB) & 7(RFP/INH) | I | 34 |
| 18 | 40,M | PPD+, smear+, C- | 12 | + | - | + | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 28 |
| 19 | 50,M | PPD+, smear+, C- | 2 | + | - | + | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 29 |
| 20 | 36,F | PPD+, PCR- | 4 | + | + | + | 4(Rifapentine/INH/PZA/EMB) & 9(Rifapentine/INH) | II | 40 |
| 21 | 60,F | PPD+, smear+, C- | 2 | + | + | + | 4(Rifapentine/INH/PZA/EMB) & 9(Rifapentine/INH) | II | 38 |
| 22 | 55,F | PPD+ | 6 | + | - | + | 4(RFP/INH/PZA/EMB) & 2(RFP/INH/EMB) & 12(RFP/INH) | III | 32 |
| 23 | 60,M | PPD+ | 8 | + | - | + | 4(RFP/INH/PZA/EMB) & 8(RFP/INH) | II | 27 |
: positive;
: negative;
*: severe case,
: knee TB,
: type 2 diabetes,
: symptoms commonly associated with tuberculosis, including low-grade fever, night sweats, anorexia and marasmus.
Good efficacy of drug treatment in nine suspected patients named group I; moderate efficacy of drug treatment in four confirmed and ten suspected patients named group II; poor efficacy of drug treatment in three confirmed and four suspected patients named group III.